CAR_Public/030417.mbx                C L A S S   A C T I O N   R E P O R T E R
  
                Thursday, April 17, 2003, Vol. 5, No. 76

                              Headlines                            

CATHOLIC CHURCH: Long Island Diocese Faces Billion-Dollar Abuse Suits
DYNACQ INTERNATIONAL: Asks TX Court To Dismiss Securities Fraud Lawsuit
DYNACQ INTERNATIONAL: Asks TX Court To Dismiss Stock Derivative Lawsuit
EASY-BAKE: Recalls 155T Cookie Making Sets Over Undeclared Ingredients
HOMEGOLD FINANCIAL: Investors Seek To Recover Losses in New Fraud Suit

INDUMAR SEAFOOD: Recalls Crab Claw Meat Containers Due To Contamination
INTERLAND INC.: ID Court Conditionally Certifies Employee Wage Lawsuit
MICROSOFT CORPORATION: Settling Florida Antitrust Suit For $202M
NIKE INC.: OR Court Grants Approval to Securities Fraud Suit Settlement
PHILIP MORRIS: To Remove "Light" From Packages in Aftermath of Lawsuit

PLAYSKOOL: Voluntarily Recalls 300T Magic Start Toys For Injury Hazard
RHEE BROS.: Recalls Chamdel Korean Cookies Over Undeclared Ingredients
SINCERE TRADING: Recalls Sweetened Coconut Over Undeclared Ingredients
SOLECTRON CORPORATION: Investors File Securities Fraud Suits in N.D. CA
SOLECTRON CORPORATION: Faces Shareholder Derivative Lawsuit in CA Court

SUPERGEN INC.: Shareholders Launch Suit For Securities Violations in CA
SWATT BAKING: Recalls Salt Rising Bread Due to Undeclared Ingredients
ULTRA HEALTH: Warns V. Using Vinarol Tablets due To Hazards To Health

                     New Securities Fraud Cases

ACCREDO HEALTH: Barrett Johnston Lodges Securities Lawsuit in W.D. TN
ADC TELECOMMUNICATIONS: Marc Henzel Lodges Securities Suit in MN Court
AFFYMETRIX INC.: Marc Henzel Commences Securities Fraud Suit in N.D. CA
AMERCO: Marc Henzel Commences Suit For Securities Violations in Nevada
CERNER CORPORATION: Marc Henzel Lodges Securities Fraud Suit in W.D. MO

CIT GROUP: Marc Henzel Commences Securities Fraud Lawsuit in S.D. NY
CORE LABORATORIES: Marc Henzel Commences Securities Lawsuit in S.D. NY
EL PASO: Stull Stull Launches Suit For Securities Violations in W.D. TX
FISCHER IMAGING: Marc Henzel Commences Securities Fraud Lawsuit in CO
I2 TECHNOLOGIES: Shapiro Haber Lodges Securities Fraud Suit in TX Court

I2 TECHNOLOGIES: Marc Henzel Commences Securities Fraud Suit in N.D. TX
I2 TECHNOLOGIES: Stull Stull Commences Securities Fraud Suit in N.D. TX
IMPERIAL CHEMICAL: Marc Henzel Commences Securities Lawsuit in S.D. NY
PEC SOLUTIONS: Finkelstein Thompson Launches Securities Suit in E.D. VA
PHARMACIA CORPORATION: Scott + Scott Lodges Securities Fraud Suit in NJ

PHARMACIA CORPORATION: Cauley Geller Lodges Securities Fraud Suit in NJ
PHARMACIA CORPORATION: Schiffrin & Barroway Files Securities Suit in NJ
PHARMACIA CORPORATION: Alfred Yates Lodges Securities Fraud Suit in NJ
SUPERGEN INC.: Charles Piven Lodges Securities Fraud Lawsuit in N.D. CA
SYMBOL TECHNOLOGIES: Marc Henzel Commences Securities Suit in E.D. NY

TRANSKARYOTIC THERAPIES: Marc Henzel Commences Securities Suit in MA
ULTIMATE ELECTRONICS: Marc Henzel Commences Securities Fraud Suit in CO

                              *********

CATHOLIC CHURCH: Long Island Diocese Faces Billion-Dollar Abuse Suits
---------------------------------------------------------------------
Priests and church hierarchy of Long Island's Diocese of Rockville
Centre in New York face two suits seeking more than $1 billion for
victims of sexual abuse by priests, the Associated Press reports.  The
suits also allege that the nation's sixth largest Roman Catholic
diocese did nothing to protect victims from abuse and sought to protect
its own reputation, instead.

Three dozen parishioners filed the first suit, naming as defendants
Bishop William Murphy, thirteen priests who allegedly sexual abused
parishioners and other church leaders.  The first suit seeks $100
million in compensatory damages, $100 million in punitive damages and
$100 million for pain and suffering.

Another lawsuit was filed on behalf of 11 alleged victims.  The suit
charged church leaders with committing a fraud on the public, by
allowing children to attend schools and church functions where they
knew pedophile priests to be present.  The suit seeks $1 billion in
punitive damages, $100 million for pain and suffering and $50 million
for special damages

"This is about the Catholic Church putting the church ahead of children
that they were obligated to protect," Michael Dowd, a lawyer
representing 23 plaintiffs in one of the lawsuits, told AP.  "This is
very much about the church's refusal to accept responsibility."

A plaintiff in the second lawsuit Brian Dionne, now 51, said in a press
conference, "our childhood was stolen."  Mr. Dionne was allegedly
abused by a priest in Kings Park and has been in therapy since he was
28, according to an AP report.  "Most of us who were victims in this
way suffered this alone," he said.

After the first lawsuit was filed, diocese spokeswoman Joanne Novarro
told AP that "the diocese intends to defend this case vigorously, as
any other institution in our society has a right and an obligation to
do."


DYNACQ INTERNATIONAL: Asks TX Court To Dismiss Securities Fraud Lawsuit
-----------------------------------------------------------------------
Dynacq International, Inc. asked the United States District Court for
the Southern District of Texas to dismiss the consolidated securities
class action filed against it and two of its officers, alleging
violations of federal securities laws and regulations.

The putative class covers those persons who purchased the Company's
shares between November 29, 1999 and January 16, 2002.  The suit claims
that the Company violated Sections 10(b) and 20(a) and Rule 10b-5 under
the Securities Exchange Act of 1934 by making materially false or
misleading statements or omissions regarding revenues and receivables
and regarding whether the Company's operations complied with various
federal regulations.

The Company and the officers moved to dismiss the complaint on February
25, 2003.  Plaintiffs have not yet filed their response to that motion.
Because no discovery can take place unless and until the case survives
the motion to dismiss, this action remains at an early stage.  The
Company intends to defend these claims vigorously.


DYNACQ INTERNATIONAL: Asks TX Court To Dismiss Stock Derivative Lawsuit
---------------------------------------------------------------------
Dynacq International asked the 295th District Court of Harris County,
Texas to dismiss a shareholder derivative suit brought on behalf of
the Company against its officers and directors, outside auditor, and
investment bank, and two analysts affiliated with that investment bank.

The suit alleges breach of fiduciary duty, aiding and abetting breach
of fiduciary duty, negligence and breach of contract.  Plaintiff makes
general allegations of the defendants' alleged misconduct in:

     (1) causing or allowing the Company to conduct its business in an
         unsafe, imprudent and unlawful manner;

     (2) failing to implement and maintain an adequate internal control
         system; and

     (3) exposing the Company to enormous losses," including     
         allegations that various press releases and/or public  
         statements issued between January 1999 and January 2002
         were misleading.

Plaintiffs further allege sales by the Company's insiders while in
possession of material non-public information.  The plaintiffs made no
demand on either the Company or its Board of Directors prior to filing
suit.  

A separate action was brought in United States District Court for the
Southern District of Texas making similar allegations in federal court
against only officers and directors of the Company.  The plaintiff in
this action also did not make a demand to the Company prior to filing
suit.  Another derivative suit making similar allegations was filed in
152nd District Court of Harris County, Texas; however, at the
plaintiff's request, the Court dismissed that action.

The Board of Directors has appointed a Special Litigation Committee to
conduct an investigation and make a determination as to how the Company
should proceed on the claims asserted in the state-court shareholder
derivative case. On February 24, 2003, the Special Litigation Committee
adopted a resolution directing the Company's counsel to seek dismissal
of the state-court derivative action.  The Company has filed a motion
to dismiss, but it has not yet been set for hearing.  The federal court
derivative lawsuit has been stayed pending resolution of the
shareholder class action.  The derivative matters, if they proceed, do
not seek to recover any damages from the Company, but may expose the
company to bearing some unknown legal or indemnity costs.


EASY-BAKE: Recalls 155T Cookie Making Sets Over Undeclared Ingredients
----------------------------------------------------------------------
EASY-BAKE is voluntarily recalling approximately 155,000 of its EASY-
BAKE BAKE `N DESIGN COOKIE SETS, product nos. 60813/60821 and
60814/60821, because the white cookie mix included in the sets contains
milk proteins and may contain peanuts, both of which were not declared
on the label.  People who have an allergy or severe sensitivity to milk
proteins or peanuts run the risk of serious or life-threatening
allergic reaction if they consume these products.

No complaints or illnesses have been reported to date in the US.  One
illness has been reported in Canada.

The EASY-BAKE BAKE `N DESIGN COOKIE SET was sold in a purple and pink
box with the EASY-BAKE logo on the outside and included a white cookie
mix, icing mix, two food decorating pens and four cookie cutters.  The
product no. 60813/60821 or 60814/60821 is featured on the lower right
corner of the packages front panel.  The sets were sold in the US at
major toy stores and mass merchandise outlets nationwide beginning in
November 2001 and cost approximately $6.99.

No other EASY-BAKE products or mixes are affected by this recall.

For more details, contact the Company by Phone: 800-327-8264 or visit
the firm's Website: http://www.easybake.com.


HOMEGOLD FINANCIAL: Investors Seek To Recover Losses in New Fraud Suit
----------------------------------------------------------------------
Former and current officers of Homegold Financial, Inc. and subsidiary
Carolina Investments face a lawsuit filed by 15 investors on behalf of
people who deposited money with Carolina Investors before the Company
shut down three weeks ago, the Independent-Mail reports.  The suit came
as HomeGold prepared for a hearing Tuesday in US Bankruptcy Court in
Columbia.

Attorneys Stan Jackson and W. Trey Merck filed the suit, as they
invested a total of $647,000 plus interest with Carolina.  The suit
named the two companies as responsible parties, but stopped short of
naming them as defendants because the companies have filed for
bankruptcy protection.  This could further complicate the matter, and
lengthen the time it takes to recover the investors' money, Mr. Jackson
told the Independent-Mail.

"This was basically a life's savings," said Mr. Jackson, who primarily
argues similar class action civil suits.  He added, the company was
wrong "to lend $275 million without security."

"We are holding these officers and directors responsible, and we want
to find out where the money went and get it back," he said Tuesday,
according to Independent-Mail.

The suit seeks for the money that everyone lost, plus 6 percent
interest and attorneys fees.  Once the bankruptcy process begins a
conservator will be appointed, who will help to decide how the assets
will be handled, Mr. Jackson added.


INDUMAR SEAFOOD: Recalls Crab Claw Meat Containers Due To Contamination
-----------------------------------------------------------------------
Indumar Seafood Corporation of Weston, Florida is recalling its 16 oz.
Plastic containers of Caribe Brand Fresh Crab Claw Meat, Product of
Venezuela, because it has the potential to be contaminated with
Listeria monocytogenes, an organism which can cause serious and
sometimes fatal infections in young children, frail or elderly people,
and others with weakened immune systems.

Although healthy individuals may suffer only short-term symptoms such
as high fever, severe headache, stiffness, nausea, abdominal pain and
diarrhea, listeria infection can cause miscarriages and stillbirths
among pregnant women.

Caribe brand Fresh Crab Meat affected was distributed in Georgia,
Texas, Pennsylvania, Maryland, and New York through retail outlets.

Caribe brand Fresh Crab Meat is packed in clear plastic 16-oz.
containers with blue printing.  The container has no code numbers or
expiration dates.  The "Claw" box is checked (X), indicating claw meat
only.

No illnesses have been reported to date.  The recall was the result of
a routine sampling by the Food and Drug Administration, which revealed
that the finished product contained the bacteria.

For more details, contact the company by Phone: 1-800-INDUMAR.


INTERLAND INC.: ID Court Conditionally Certifies Employee Wage Lawsuit
----------------------------------------------------------------------
The United States District Court for the District Court of Idaho
conditionally certified a class in the employee suit filed against
Interland, Inc. by five individual plaintiffs, who claim they were
employees of Micron Electronics Inc. between 1999 and April 2001.  The
plaintiffs claim that they, and other similarly situated employees, did
not receive overtime pay to which they were entitled under the Fair
Labor Standards Act.

This potential liability remains with Interland even though it sold the
PC Systems business.  Interland disputes these claims and believes the
plaintiffs are not entitled to any material additional wages.  The
court conditionally certified a class of not more than eight hundred
former employees and notices of the litigation are being sent to these
persons to give them the opportunity to "opt in" to the litigation.  
The parties are continuing to conduct discovery.  At this early stage
of the litigation the Company is unable to estimate its total expenses,
possible loss or range of loss that may ultimately be connected with
the matter.


MICROSOFT CORPORATION: Settling Florida Antitrust Suit For $202M
----------------------------------------------------------------
Software giant Microsoft Corporation agreed to settle for US$202
million a class action filed by Florida residents alleging the Company
violated a state law against unfair trade practices in the way it sold
its operating system and applications software, the Associated Press
reports.  The suit was filed in Florida Circuit Court in Miami.

Under the settlement, the Company agreed to provide $202 million in
vouchers for people to buy computers and related products.  Half of any
unclaimed vouchers will be given to Florida public schools, the company
said.  The settlement is applicable to class action participants who
purchased the Microsoft operating system, productivity suite,
spreadsheet or word processing software between November 16, 1995, and
December 31, 2002.  These participants will be eligible for vouchers to
purchase computer hardware and software from any manufacturer.

Half of the total value of any unclaimed vouchers will be given to
Florida's most needy public schools, Microsoft said in a statement.  
The company didn't say when the vouchers would expire if not used, the
Associated Press reports.

Bill Piotrowski, executive director of technology and information
services for Leon District Schools in Tallahassee, Fla., told AP the
settlement was "great news for schools all across Florida."

"Given the tough budget environment, the timing is particularly
helpful," he said in a statement. "This program will provide badly
needed resources for the schools that need it most and help bridge the
digital divide for those students."

The final settlement approval hearing is set for November 24, 2003.  


NIKE INC.: OR Court Grants Approval to Securities Fraud Suit Settlement
-----------------------------------------------------------------------
The United States District Court for the District of Oregon granted
approval to the US$8.9 million settlement proposed by Nike, Inc. to
settle a consolidated securities class actions filed against on behalf
of purchasers of Nike Inc. (NYSE:NKE) common stock between December 20,
2000 and February 26, 2001.

The suit, filed in the United States District Court for the District of
Oregon, charges the Company and certain of its executive officers with
violations of Section 10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder, an earlier Class Action
Reporter story states.  Specifically, the suit alleges that the
defendants repeatedly issued materially false and misleading statements
regarding its third quarter earnings and revenues.

The Company paid $8.9 million in cash, funded by the Company's
directors and officers liability insurance.  In the settlement, the
Company and the officers and directors named in the lawsuits do not
admit, and continue to deny, any and all allegations of wrongdoing, and
they received a full release of all claims asserted in the litigation.


PHILIP MORRIS: To Remove "Light" From Packages in Aftermath of Lawsuit
----------------------------------------------------------------------
Tobacco giant Philip Morris USA will remove controversial "light"
wording from some of its packages, Reuters reports, in the aftermath of
a lawsuit filed against it, alleging it deceived smokers into thinking
light cigarettes were safer than regular smokes.

Madison County Judge Nicholas Byron ruled that the Company should pay
$10.1 billion as a bond for the suit.  Philip Morris said the ruling
might drive it to bankruptcy and cause it to default on its payments
for a 1998 settlement with several states.  Yesterday, the Company won
a minor victory as Judge Byron ordered it to pay only half of the
original bail bond.

The Company made the decision in response to a health report issued by
the National Cancer Institute in 2001 and before it was ordered to pay
$10.1 billion by an Illinois judge in the class-action "lights" case,
Philip Morris USA spokesman Brendan McCormick told Reuters.

Philip Morris USA will remove the words "lowered tar and nicotine" from
packages of Marlboro Lights and will remove references to low tar on
other cigarettes, he said.  The company hopes to complete the change by
the end of the year, he said.

Attorneys for the plaintiffs in the Illinois case said on Tuesday that
Philip Morris USA had said it would remove the words "lowered tar and
nicotine" from packages of its Marlboro Light cigarettes during a
closed-door hearing to determine the size of bond Philip Morris USA
would have to post to appeal the verdict.


PLAYSKOOL: Voluntarily Recalls 300T Magic Start Toys For Injury Hazard
----------------------------------------------------------------------
Playskool is cooperating with the United States Consumer Product Safety
Commission (CPSC) by voluntarily recalling about 300,000 Magic Start
Crawl 'n Stand toys.  The toy, which is designed to encourage crawling
babies to pull themselves up and stand, can tip over during use and
strike falling babies in the head, face or neck, resulting in injuries.
        
Playskool has received 44 reports of the toys tipping over during
use.  There have been 26 reports of babies suffering injuries,
including one minor concussion, and various bumps, bruises, black eyes
and cut lips.
        
The Playskool(r) Magic Start Crawl 'n Stand is a multicolor plastic toy
with a round base and three arched legs that support an electronic
activity center.  When crawling babies touch the frame of the toy,
music, lights and spinning balls are activated.  Babies can pull
themselves up on the legs of the toy to play at the activity center.  
The Playskool logo is imprinted into the plastic base and on top of the
activity center.  Writing under the activity center includes "ITEM #
06952" and "Made in China."
        
Wal-Mart stores nationwide sold these toys from November 2002 through
April 2003 for about $14.
        
For more information, contact the Company by Phone: 800-509-9554 or
visit the firm's Website: http://www.playskool.com


RHEE BROS.: Recalls Chamdel Korean Cookies Over Undeclared Ingredients
----------------------------------------------------------------------
RHEE BROS., INC. of Columbia, MD is recalling its 6.34-ounce packages
of `Chamdel' brand `Korean Cookies' because they may contain undeclared
milk protein.  People who have allergies to milk run the risk of
serious or life-threatening allergic reaction if they consume these
products.

The recalled `Chamdel' brand `Korean Cookies' was distributed in retail
stores on the East Coast.  The product comes in 6.34-ounce packages
labeled as `Chamdel' and `Korean Cookies.'  The code on the package is
09762K.

No illnesses have been reported to date in connection with this
problem.  The recall was initiated after sampling by 'New York State
Department of Agriculture & Markets' food inspectors discovered that
the milk protein-containing product was distributed in packaging that
did not reveal the presence of a milk ingredient.

Consumers who have purchased 6.34-ounce packages of 'Chamdel' brand
'Korean Cookies' are urged to return them to the place of purchase for
a full refund.  Consumers with questions may contact the company at 1-
410-381-9000.


SINCERE TRADING: Recalls Sweetened Coconut Over Undeclared Ingredients
----------------------------------------------------------------------
Sincere Trading Co., Inc., is recalling its 7 oz packages of "dragon
sweetened coconut" because they may contain undeclared sulfites.  
People who have severe sensitivities to sulfites run the risk of
serious or life threatening allergic reaction if they consume this
product.

The recalled "dragon sweetened coconut" was distributed nationwide to
retail stores.  The product comes in a 7 ounce sealed foil package, it
is a product of Vietnam.

The recall was initiated after routine sampling by NYS Agriculture and
Markets food inspectors discovered that the package label did not
reveal the presence of sulfites.  The consumption of 10 mgs per serving
of sulfites has been reported to elicit severe reactions in some
asthmatics.  Anaphylactic shock could occur in certain sulfite
sensitive individuals upon consumption of 10mg or more of sulfites.  
Analysis of the "dragon sweetened coconut" revealed it contains 68.51
mgs per serving.

No illnesses have been reported to date in connection with this
problem.

Consumers who have purchased "dragon sweetened coconut " are urged to
return them to the place of purchase for a full refund.  Consumers with
questions may contact the company at 718-628-6600.


SOLECTRON CORPORATION: Investors File Securities Fraud Suits in N.D. CA
-----------------------------------------------------------------------
Solectron Corporation faces several securities class actions filed in
the United States District Court for the Northern District of
California alleging claims under Section 10(b) and 20(a) of the
Securities Exchange Act of 1934, and Rule 10b-5 promulgated thereunder.  
The suit also names as defendants certain of the Company's officers and
directors.

The suits uniformly allege that the defendants issued false and
misleading statements in certain press releases and SEC filings issued
between September 17, 2001 and September 26, 2002.  In particular,
plaintiff alleges that the defendants failed to disclose and to
properly account for excess and obsolete inventory in the Technology
Solutions business unit during the relevant time period.  The lawsuit
seeks an unspecified amount of damages on behalf of the putative class.

Consistent with the usual procedures for cases of this kind, the
Company anticipates that these cases (and any other similar putative
shareholder class action suits which might be filed against it) may be
consolidated into a single consolidated action.  The Company intends to
vigorously defend against the lawsuits.  However, there can be no
assurance that the outcome of these lawsuits will be favorable to the
Company or will not have a material adverse effect on its business,
financial condition and results of operations.


SOLECTRON CORPORATION: Faces Shareholder Derivative Lawsuit in CA Court
-----------------------------------------------------------------------
Solectron Corporation, all of the current members of its Board of
Directors, and two former officers, were named as defendants in a
shareholder derivative lawsuit filed in the Santa Clara County,
California Superior Court.

The plaintiff alleges that he should be permitted to pursue litigation,
purportedly for the benefit of the Company, against the individual
director and officer defendants for:

     (1) alleged mismanagement and waste of corporate assets during the
         period from May 2001 to the present, purported breaches of
         fiduciary duty,

     (2) constructive fraud,

     (3) abuse of control, and

     (4) alleged violations of the California Corporations Code by
         certain of the individual defendants who sold some of their
         Company stockholdings during the period from September 2001
         through September 2002.

The complaint seeks an unspecified amount of compensatory and punitive
damages, and the relinquishment of all profits realized by those
individual defendants who sold Solectron stock during the relevant
period, together with statutory penalties under California Corporations
Code section 25402 which plaintiff alleges to be applicable to those
sales of Solectron stock.  Solectron does not believe plaintiff has
adequately alleged a basis for plaintiff to appropriate for himself the
duties of Solectron's Board of Directors under applicable Delaware law,
and intends to seek dismissal of the lawsuit.


SUPERGEN INC.: Shareholders Launch Suit For Securities Violations in CA
-----------------------------------------------------------------------
Supergen, Inc. faces a class action filed against it in the United
States District Court for the Northern District of California by
prominent law firm Milberg Weiss Bershad Hynes & Lerach LLP on behalf
of purchasers of SuperGen Inc. (NASDAQ:SUPG) common stock during the
period between April 18, 2000 and March 13, 2003, the Contra Costa
Times reports.

The complaint charges SuperGen and its chairman, president and chief
executive officer with violations of the Securities Exchange Act of
1934, an earlier Class Action Reporter story states. The suit alleges
the Company withheld critical information about its leading cancer drug
candidate when it sold millions of shares and notes for $25 million
during the class period.  The suit further asserts that the company
knew but did not disclose that the drug caused adverse reactions such
as fever, anorexia, nausea and vomiting and that it made claims about
the benefits of drug that weren't true.

CEO Joseph Rubinfeld said the lawsuit is without merit, according to
Contra Costa Times.


SWATT BAKING: Recalls Salt Rising Bread Due to Undeclared Ingredients
---------------------------------------------------------------------
Swatt Baking Company of Olean, New York, April 10, 2003, recalled 16-
oz. loaves of Salt Rising Bread because it may contain undeclared milk
protein.  People who have allergies to milk protein may run the risk of
serious or life-threatening allergic reaction if they consume this
product.

The recalled 16-oz. loaves of Salt Rising Bread, coded sell by 12-18
(2002), were sold through retail stores and direct delivery in Western
New York and Northwest Pennsylvania.

The recall was initiated after routine sampling by New York State
Department of Agriculture and Markets Food Inspectors revealed the
presence of undeclared milk protein in Salt Rising Bread in packages
which did not declare a milk ingredient on the label.  Subsequent
investigation revealed a printing error on the package.

No illnesses have been reported to date in connection with this
problem.  Consumers who have purchased Salt Rising Bread should return
it to the place of purchase.


ULTRA HEALTH: Warns V. Using Vinarol Tablets due To Hazards To Health
---------------------------------------------------------------------
Ultra Health Laboratories, Inc. and Bionate International, Inc. is
cooperating with the United States Food and Drug Administration by
issuing warnings to consumers not to purchase or consume a product
known as Vinarol tablets.

This product, which is being marketed as a dietary supplement, contains
the unlabeled prescription drug ingredient, sildenafil, which may pose
possible serious health risks to some users.  Vinarol is marketed in
tablet form in blister packages of 2 and 7 tablets and is labeled as
distributed by Ultra Health Laboratories, Inc. and/or Bionate
International, Inc.  The product is being promoted for increasing
desire, confidence and sexual performance and is sold over the counter,
as well as, via the Internet.

The interaction between nitrates and sildenafil can result in profound
and life-threatening lowering of blood pressure.  The use of nitrates
in any form is an absolute contraindication for sildenafil users.  The
potential for this product to be taken by unknowing nitrate users is
real, since erectile dysfunction is often a concurrent condition in
patients with diabetes, hypertension, hyperlipidemia, smokers and
patients with ischemic heart disease.

Ultra Health Products, Inc. and Bionate International, Inc. to date
have not received any reports of injury or adverse reactions from the
use of this product.

For more details, contact the Company by Mail: Ultra Health
Laboratories, Inc. at 3249 East Harbour Drive, Phoenix, Arizona 85034
by Phone: 1-800-796-1150 or visit FDA's MedWatch program's Website:
http://www.accessdata.fda.gov/scripts/medwatch/.


                     New Securities Fraud Cases

ACCREDO HEALTH: Barrett Johnston Lodges Securities Lawsuit in W.D. TN
---------------------------------------------------------------------
Barrett Johnston & Parsley initiated a securities class action in the
United States District Court for the Western District of Tennessee on
behalf of purchasers of Accredo Health, Inc. (Nasdaq:ACDO) publicly
traded securities during the period between June 16, 2002 and April 7,
2003.

The complaint charges Accredo and certain of its officers and directors
with violations of the Securities Exchange Act of 1934.  Accredo
provides specialized contract pharmacy and related services pursuant to
agreements with biotechnology drug manufacturers relating to the
treatment of patients with certain costly, chronic diseases.

The complaint charges that during the class period, defendants caused
Accredo's shares to trade at artificially inflated levels through the
issuance of false and misleading financial statements.  The true facts,
which were known by the defendants but actively concealed, were:

     (1) The Company's Q4 02 to Q2 03 results were grossly overstated.
         Prior to the Company's acquisition of the Specialty
         Pharmaceutical Services (SPS) division of Gentiva Health
         Services, the Company was reserving 12% of gross patient
         receivables as an allowance for doubtful accounts.  After
         completing due diligence of SPS in May/June 2002, defendants
         realized that if they revealed the truth about the
         consolidated receivables it would negatively impact the
         Company's receivables and net income;

     (2) The Company's hemophilia product line was not tracking with
         the Company's projections.  This product line was very
         material to the Company as it represented 30% of the Company's
         gross revenue and was the Company's highest gross margin
         business line (35%-40% vs. consolidated margins of 20%); and

     (3) As a result of the above, the Company's fiscal 2003 revenue
         projections of $1.45 billion and EPS projections of $1.33
         $1.38 were grossly inflated.

For more details, contact Tim Miles by Phone: (615) 244-2202 or by E-
mail: Tmiles@barrettjohnston.com


ADC TELECOMMUNICATIONS: Marc Henzel Lodges Securities Suit in MN Court
----------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the District of Minnesota, on
behalf of all persons who purchased the common stock of ADC
Telecommunications, Inc. (Nasdaq: ADCT) between November 28, 2000 and
March 28, 2001, inclusive, against the Company and certain officers of
the Company.

The complaint alleges that ADC and certain of its officers violated
federal securities laws by making false and misleading statements and
material omissions regarding ADC's financial prospects.  The complaint
further alleges that during the class period, defendants represented
numerous times that ADC would maintain considerable growth and would be
unaffected by broadly known declines in capital spending from
communications service providers on the telecommunications
infrastructure.

On March 28, 2001, defendants disclosed that the Company's fiscal 2001
earnings guidance, issued four weeks prior, would be reduced.  ADC also
announced that approximately 4,000 jobs would be cut and facilities
closed as the Company experienced canceled orders and decreasing
revenues resulting from the declines in equipment spending by
telecommunications service providers.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


AFFYMETRIX INC.: Marc Henzel Commences Securities Fraud Suit in N.D. CA
-----------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the Northern District of
California on behalf of purchasers of Affymetrix, Inc. (Nasdaq: AFFX)
publicly traded securities during the period between January 29, 2003
and April 3, 2003, inclusive.

The complaint charges Affymetrix with a violation of Section 10(b) of
the Exchange Act and Rule 10b-5 promulgated thereunder and certain of
its officers and directors with a violation of Section 20(a) of The
Exchange Act.  More specifically, on January 29, 2003, the Company
issued a press release, announcing its financial results for the fourth
quarter 2002 and fiscal year 2002, wherein it advised that the Company
expected to achieve product revenue growth of 28% in 2003 and expected
that product revenue for the first quarter of 2003 would range between
$71-73 million.

However, these prospects lacked a reasonable basis as they failed to
disclose that the Company was experiencing declining demands for its
products and services, was taking numerous steps to hide the
deterioration in its business, and would no longer be able to conceal
the slowdown in its sales from investors.  What is more shocking is
that the Company, not less than three months after reporting their
bright product revenue outlook, reported that its expectations for
first quarter growth were significantly lower, such that product
revenue growth would only be between $60-62 million.

News of the lower product revenue figures sent the Company's common
stock in a rapid decline. Additionally shocking is that about eleven
days prior to the Company's announced low first quarter figures,
GlaxoSmithKline PLC (who share a common director with Affymetrix)
engaged in a sale of 4,736,254 shares of Affymetrix common stock, which
resulted in a $124,557190.30 windfall for GlaxoSmithKline PLC.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


AMERCO: Marc Henzel Commences Suit For Securities Violations in Nevada
----------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the District of Nevada, on
behalf of purchasers of Amerco (Nasdaq: UHAL) publicly traded
securities during the period between February 12, 1998 and September
26, 2002, inclusive.

The complaint charges Amerco and certain of its officers and directors
with violating the federal securities laws by issuing false and
misleading statements during the class period.  Specifically, the
complaint alleges that during the class period, defendants caused
Amerco to engage in transactions with SAC Holding Corporation and SAC
Holding Corporation II (SAC Holdings), which falsely improved Amerco's
financials, and which served to benefit Amerco insiders to the
detriment of Amerco shareholders.

According to the complaint, defendants failed to disclose the true
nature and financial impact of the transactions to the public.  The
complaint further alleges that Amerco failed to disclose that
Defendants used Amerco's resources to identify, purchase, and/or
develop self-storage properties, which it then sold to SAC Holdings for
inadequate consideration or caused SAC Holdings to buy.  SAC Holdings,
owned and controlled by Amerco insiders, thereby received substantial
benefit from transactions which otherwise served to falsely improve
Amerco's financials.

On September 26, 2002, Amerco restated its 2002 financial results in an
amended 10-K for the year ended March 31, 2002, and restated its 2001
and 2000 financials for the second time.  The complaint charges that as
a result of the defendants' false and misleading statements during the
Class Period, Amerco's stock price was artificially inflated, averaging
approximately $18 per share.  In the weeks following news of the above
events, Amerco's share price tumbled to less than $5, causing Plaintiff
and other members of the Class to suffer damages, according to the
complaint.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


CERNER CORPORATION: Marc Henzel Lodges Securities Fraud Suit in W.D. MO
-----------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the Western District of
Missouri, on behalf of purchasers of Cerner Corporation (Nasdaq: CERN)
publicly traded securities during the period between January 23, 2003
and April 2, 2003, inclusive.

The complaint alleges that defendants violated Sections 10(b) and 20(a)
of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated
thereunder, by issuing a series of material misrepresentations to the
market between January 23, 2003 and April 2, 2003, thereby artificially
inflating the price of Cerner common stock.

The complaint alleges that these statements were materially false and
misleading because they failed to disclose and misrepresented the
following adverse facts, among others:

     (1) that the Company was experiencing an increased level of
         competition as competitors slashed prices in order to take
         business from the Company.  As a result, the Company was
         losing a material amount of sales to competitors;

     (2) that certain of the Company's clients were delaying or
         deferring the purchase of products from the Company or
         determining not to proceed with those purchases at all;

     (3) that the Company had reorganized its sales force and that the
         reorganization was negatively impacting the ability of the
         Company to close certain sales; and

     (4) as a result of the foregoing, defendants' earnings projections
         were lacking in a reasonable basis at all times and were
         materially false and misleading.

On April 3, 2003, Cerner shocked the market by announcing that "it
expects its first quarter 2003 revenue and earnings to be below
expectations because of a lower level of new business bookings in the
quarter."  The press release further revealed that the Company expected
bookings for the first quarter of 2003 to be between $145 and $150
million and that earnings would be between $0.13 to $0.15 per share as
compared to analysts earnings estimates of $0.38 per share.

In response to this announcement, the price of Cerner common stock
declined precipitously falling from $32.09 per share to as low as
$18.35 per share on extremely heavy trading volume.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


CIT GROUP: Marc Henzel Commences Securities Fraud Lawsuit in S.D. NY
--------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the Southern District of New
York, on behalf of persons who purchased the common stock of CIT Group
Inc. (NYSE: CIT) in or traceable to the Company's initial public
offering commenced on or about July 1, 2002, and who have been damaged
thereby.  The action is pending against the Company, Albert R. Gamper,
Jr. (CEO and President) and Joseph M. Leone (CFO).

The complaint charges that defendants violated Sections 11, 12(a)(2)
and 15 of the Securities Act of 1933 because CIT's IPO registration
statement and prospectus contained materially false and misleading
statements of fact.  The complaint alleges, among other things, that
the Prospectus falsely represented that CIT's reserves for losses in
its telecommunications finance portfolio were "adequate" despite recent
declines in the sector, which were expected to continue.

In addition, the Prospectus further characterized as adequate its
reserves for credit losses in general.  According to the complaint,
these statements were materially false and misleading when made
because, among other reasons, they failed to disclose that the
Company's loan loss reserves for its finance portfolio in the
telecommunications industry, and its loan portfolio in general, were
materially deficient in light of material credit losses that had
already been incurred.

The complaint further alleges that the Company's assets and
shareholders' equity were overstated in the Prospectus by reason of the
foregoing.  On July 23, 2003, CIT announced that it took a $200 million
charge to strengthen the telecommunications loan reserves that it
represented were adequate only three weeks previously. On April 8,
2003, the price of CIT common stock closed at $17.40 per share, which
is 24% lower than the IPO price of $23 per share.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


CORE LABORATORIES: Marc Henzel Commences Securities Lawsuit in S.D. NY
----------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the Southern District of New
York on behalf of all purchasers of the common stock of Core
Laboratories, N.V. (NYSE: CLB) from May 6, 2002 through March 31, 2003,
inclusive.

The complaint alleges that defendants violated Sections 10(b) and 20(a)
of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated
thereunder, by issuing a series of material misrepresentations to the
market between May 6, 2002, and March 31, 2003, thereby artificially
inflating the price of Core common stock.

Throughout the class period, as alleged in the Complaint, defendants
issued numerous statements and filed quarterly reports with the SEC
which described the Company's increasing financial performance.  The
complaint alleges that these statements were materially false and
misleading because they failed to disclose and/or misrepresented the
following adverse facts, among others:

     (1) that the Company had materially overstated its net income and
         earnings per share;

     (2) that the Company had overstated its ability to collect on
         certain accounts receivable;

     (3) that the Company had improperly delayed the booking of
         expenses and foreign exchange translation losses from certain
         field locations;

     (4) that the Company lacked adequate internal controls and was
         therefore unable to ascertain the true financial condition of
         the Company; and

     (5) that as a result, the value of the Company's net income and
         financial results was materially overstated at all relevant
         times.

On March 31, 2003, after the markets had closed trading for the day,
the Company shocked the market by announcing that it would be restating
its financial results for prior 2002 quarterly operating results
because of:

     (i) the issuance of duplicate invoices in the Company's Mexico
         operations;

    (ii) the need for higher provisions for doubtful accounts
         receivables;

   (iii) the need for timely booking of expenses and foreign exchange
         translation losses from certain field locations;

    (iv) changes in the estimated life of certain assets; and

     (v) consolidation costs of two Nigerian offices

Following this announcement, shares of Core common stock fell $1.31 per
share, or more than 12.5%, to close at $9.09 per share, on volume of
515,300 shares traded, or almost four times the average daily volume.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


EL PASO: Stull Stull Launches Suit For Securities Violations in W.D. TX
-----------------------------------------------------------------------
Stull Stull & Brody initiated a securities class action in the United
States District Court for the Western District of Texas, on behalf of
all persons who purchased or otherwise acquired the securities of El
Paso Electric Company (NYSE: EE) between February 14, 2000 and October
21, 2002, inclusive against the Company and:

    (1) Terry D. Bassham,

    (2) Julius F. Bates,

    (3) James Haines, Jr.,

    (4) Gary R. Hedrick and

    (5) Eduardo A. Rodriguez

The complaint charges that defendants violated Sections 10(b) and 20(a)
of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated
thereunder.  Specifically, the suit alleges that the Company issued
materially false and misleading information by misrepresenting and/or
omitting adverse facts concerning illegal arrangements with Enron
Corporation and by artificially inflating revenues.

Following an investigation by the Federal Energy Regulatory Commission,
which stated the Company was very likely involved in illegal
transactions, the price of common stock dropped dramatically.

For more details, contact Tzivia Brody by Mail: 6 East 45th Street, New
York NY 10017 by Phone: 1-800-337-4983, by Fax: 212-490-2022 or by E-
mail: SSBNY@aol.com


FISCHER IMAGING: Marc Henzel Commences Securities Fraud Lawsuit in CO
---------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the District of Colorado, on
behalf of purchasers of Fischer Imaging Corporation (Nasdaq: FIMG)
publicly traded securities during the period between February 14, 2001
and April 1, 2003, inclusive.

The complaint charges Fischer Imaging with a violation of Section 10(b)
of the Securities Exchange Act and Rule 10b-5 promulgated thereunder
and certain of its officers and directors with a violation of Section
20(a) of the Securities Exchange Act.  During the class period, the
defendants issued and/or failed to correct false and misleading
financial statements and press releases concerning the Company's
publicly reported revenues and earnings directed to the investing
public.

On April 1, 2003, Fischer Imaging announced in a press release that
based on a review being conducted by the Company in conjunction with
Ernst & Young LLP, the Company would delay the filing of its annual
report on Form 10-K for the year ended December 31, 2002.  Based on the
Fischer's preliminary findings, the Company believes it will be
necessary to restate its financial statements for the first three
quarters of 2002 and the years ended December 31, 2001 and 2000.  

The news shocked the market and investor reaction was severe.  The
value of the Company's common stock plummeted by 18.36% in one day of
trading, from a close of $5.39 on April 1, 2003 to a closing price
$4.40 on April 2, 2003.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


I2 TECHNOLOGIES: Shapiro Haber Lodges Securities Fraud Suit in TX Court
-----------------------------------------------------------------------
Shapiro Haber & Urmy LLP initiated a securities class action against i2
Technologies, Inc. (NASDAQ: ITWO) and certain of its officers and
directors on behalf of persons who purchased i2 common stock from April
21, 1999 through January 24, 2003, inclusive.  The action was filed in
the United States District Court for the District of Texas, Dallas
Division.

The complaint alleges that throughout the class period, defendants made
false and misleading statements and omissions regarding revenues and
"record" financial results in press releases and in the Company's
public filings with the SEC.

On January 27, 2003, before the market opened, i2 shocked the investing
public when it announced that it would re-audit its financial
statements for the years ended December 31, 2000 and 2001.  As a result
of this news, the price of i2's common stock fell from $1.26 per share
at the close of trading on Friday, January 24, 2002 to $0.92 per share
at the close of trading on Monday, January 27, 2002 -- a decline of
over 26%.

On March 31, 2003, the Company issued a press release announcing that
it was delaying the filing of its annual report on Form 10-K and
expanding its re-audit to include 1999 financial statements.  The
Company also disclosed that it was now the subject of a formal
investigation by the SEC.  On that same day, NASDAQ announced that it
had halted trading in i2 shares and requested additional information
from the Company.

For more details, contact Liz Hutton or Ted Hess-Mahan by Phone:
617-439-3939 or visit the firm's Website: http://www.shulaw.com


I2 TECHNOLOGIES: Marc Henzel Commences Securities Fraud Suit in N.D. TX
-----------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the Northern District of Texas
on behalf of purchasers of i2 Technologies, Inc. (Nasdaq: ITWO)
publicly traded securities during the period between April 18, 2000 and
January 24, 2003, inclusive.

The complaint alleges that defendants violated Sections 10(b) and 20(a)
of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated
thereunder, by issuing a series of material misrepresentations to the
market between April 18, 2000 and January 24, 2003, thereby
artificially inflating the price of i2 securities.

The complaint alleges that throughout the class period, in press
releases and in filings with the SEC, the Company reported increasing
revenues and "record" financial results.  As alleged in the complaint,
these statements were each materially false and misleading when made
because they failed to disclose and/or misrepresented the following
adverse facts, among others:

     (1) that the Company had materially overstated its revenue by
         improperly recognizing revenue on certain customer contracts;

     (2) that the Company lacked adequate internal controls and was
         therefore unable to ascertain the true financial condition of
         the Company; and

     (3) as a result of the foregoing, the Company's financial
         statements issued during the Class Period were materially
         false and misleading.

On January 27, 2003, before the opening of trading, i2 shocked the
investing public when it announced that it would re-audit its financial
statements for the years ended December 31, 2000 and 2001 because
"recent information developed during the audit committee's ongoing
investigation of certain allegations regarding the company's revenue
recognition with respect to certain customer contracts and its
financial reporting for those years."  The Company further reported
that it had notified the SEC of these allegations, and that the SEC
staff has begun an informal inquiry into these matters.  The Company
also advised investors that they should not rely on the financial
information contained in the company's annual reports on Form 10-K for
the years ended December 31, 2000 and 2001 or in the company's
quarterly reports on Form 10-Q for the quarters ended March 31, 2000
through September 30, 2002.

Market reaction was swift and negative, with i2 common stock falling
from a close of $1.26 on January 24, 2003 to a close of $0.92 on
January 27, 2003, the next trading day, or a single-day decline of more
than 26%, on very heavy trading volume.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


i2 TECHNOLOGIES: Stull Stull Commences Securities Fraud Suit in N.D. TX
-----------------------------------------------------------------------
Stull Stull & Brody initiated a securities class action in the United
States District Court for the Northern District of Texas, Dallas
Division, on behalf of shareholders who purchased the securities of i2
Technologies, Inc. (NASDAQ: ITWO) between April 18, 2000 and January
24, 2003, inclusive against the Company and:

     (1) Sanjiv S. Sidhu,

     (2) Gregory A. Brady,

     (3) William M. Beecher,

     (4) Nancy F. Brigham and

     (5) David C. Becker

The complaint charges that defendants violated Sections 10(b) and 20(a)
of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated
thereunder.  The action arises from damages incurred by the class as a
result of a scheme and common course of conduct by defendants which
operated as a fraud and deceit on the class during the class period.

Defendants' scheme included rendering false and misleading statements
and/or omissions concerning the present financial condition and
business prospects of the Company.  The scheme was revealed with i2
Tech announced that it would re-audit its financial statements for the
years ended December 31, 2000 and 2001 because of an ongoing
investigation of the Company's revenue recognition and its financial
reporting.

For more details, contact Tzivia Brody by Mail: 6 East 45th Street, New
York NY 10017 by Phone: 1-800-337-4983 by Fax: 212-490-2022 or by E-
mail: SSBNY@aol.com


IMPERIAL CHEMICAL: Marc Henzel Commences Securities Lawsuit in S.D. NY
----------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the Southern District of New
York, on behalf of purchasers of Imperial Chemical Industries PLC
(NYSE: ICI) American Depositary Shares (ADSs), each representing 1
pound Sterling Ordinary Share, during the period between August 1, 2002
to March 24, 2003, inclusive.

The complaint alleges that defendants violated Sections 10(b) and 20(a)
of the Securities Exchange Act of 1934, and Rule 10b-5 promulgated
thereunder, by issuing a series of material misrepresentations to the
market between August 1, 2002 and March 24, 2003, thereby artificially
inflating the price of ICI securities.  

Throughout the class period, as alleged in the complaint, defendants
issued numerous press releases in which they stated that they had
resolved the Company's distribution and software problems that the
Company had experienced at its Quest division's Fragrance & Food
businesses.  Defendants further stated that the Company was on track to
report strong financial results, that the Company had cleared its
backlog of customer orders and that the Company had not lost any
customers as a result of its production problems.

The complaint alleges that these statements were materially false and
misleading because they failed to disclose and/or misrepresented the
following adverse facts, among others:

     (1) that ICI's software, distribution and production problems at
         its Quest division were not "temporary" problems or "unique"
         to the Naarden, The Netherlands location, but impacted
         company-wide operations and profitability;

     (2) that ICI's software, distribution and production problems at
         its Quest division had not been "essentially" or "largely"
         "resolved" or "rectified"; and

     (3) that contrary to ICI's representations that it had cleared its
         backlog of orders and not lost any customers as a result of
         the software, distribution and production problems at Quest,
         ICI's customers were, in fact, obtaining new sources of supply
         and discontinuing their relationships with ICI.

On March 25, 2003, before the open of trading, ICI shocked investors
when it issued a profit warning with respect to its fiscal 2003 first
quarter.  Defendants announced that its first quarter profit would drop
approximately 24%, as a result of, among other things, "business lost
following the customer service problems in 2002."  Following this
announcement, shares of ICI fell from a close of $9.60 per share on
March 24, 2003 to a close of $5.60 per share on March 25, 2003, or a
single-day decline of more than 36%, on nearly twenty times normal
trading volume.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


PEC SOLUTIONS: Finkelstein Thompson Launches Securities Suit in E.D. VA
-----------------------------------------------------------------------
Finkelstein, Thompson & Loughran initiated a securities class action
lawsuit in the United States District Court for the Eastern District of
Virginia, on behalf of investors who purchased or otherwise acquired
the securities of PEC Solutions, Inc. (Nasdaq: PECS) between October
23, 2002 and March 14, 2003, inclusive, against the Company and certain
officers of the Company.

During the class period, defendants issued statements, press releases,
and filed reports with the SEC describing the Company's business
operations and financial condition.  The complaint alleges:

     (1) that these representations were materially false and
         misleading because they failed to disclose that throughout the
         class period, the Company was experiencing declining demand
         for its products and services as the failure of Congress to
         approve a budget for 2003 was causing governmental agencies to
         delay projects;

     (2) that the Company was experiencing material problems with
         certain of its biometric identification contracts and would
         not be generating the revenue that it had projected from those
         contracts; and

     (3) as a result, PEC Solutions was materially overstating the
         strength of its pipeline of projects and its prospects.

Additionally, during the class period, the Company failed to disclose
that it lacked adequate internal controls and was unable to ascertain
the true financial condition of the Company and was therefore
overstating the Company's financial results even as the Individual
Defendants and other Company insiders were selling their personally-
held shares of PEC Solutions common stock to the unsuspecting public
reaping proceeds of nearly $13.5 million.

On March 14, 2003, after the market closed, PEC Solutions issued a
press release announcing that it was revising guidance downwards due to
"anticipated delays in new government awards stemming from the
unusually late passing of the 2003 Federal civilian agency budgets,"
and that, "the first quarter will also be impacted by a discontinuity
in certain engagements related to application of biometric
identification technologies.  This discontinuity has extended longer
than previously expected."  This announcement shocked the market,
causing the stock to lose over 40% of its market value by dropping more
than $6 per share on 17-times its average daily volume.

For more details, contact Donald J. Enright or Conor R. Crowley by
Phone: 202-337-8000, or by E-mail: dje@ftllaw.com or crc@ftllaw.com.


PHARMACIA CORPORATION: Scott + Scott Lodges Securities Fraud Suit in NJ
-----------------------------------------------------------------------
Scott + Scott, LLC initiated a securities class action in the United
States District Court for the District of New Jersey on behalf of
purchasers of Pharmacia Corporation (NYSE: PHA) publicly traded
securities during the period between April 17, 2000 and August 21,
2001.  

The complaint charges Pharmacia and certain of its officers and
directors with violations of the Securities Exchange Act of 1934.  The
complaint alleges that according to Pharmacia, the unique feature of
Celebrex was that, unlike aspirin or ibuprofen, it allowed Celebrex to
retard pain and inflammation without the adverse side effects of
stomach malaise or gastrointestinal bleeding.

As defendants consistently stated, this critical feature of Celebrex,
provided a tremendous market advantage because the use of traditional
Nonsteroidal Anti-inflammatory Drug (NSAIDs) resulted in as many as
100,000 hospitalizations each year and more than 15,000 deaths, related
to gastrointestinal problems such as ulcers and bleeding.

In order to remove the FDA's warning label, Pharmacia was required to
demonstrate that Celebrex provided an advantage over traditional
NSAIDs.  Pharmacia then commissioned the "Celecoxib Long-term Arthritis
Safety Study" (the "CLASS" study) -- a clinical study to compare the
gastrointestinal problems of patients who used Celebrex to those of
patients who used other NSAIDs.  Pharmacia, together with its partner
Pfizer, not only funded this study, but every one of the sixteen
physicians who performed the study were either employees of or paid
consultants for Pharmacia.

Because of its purportedly unique safety profile and its ready use by
patients, Celebrex was perceived both by the medical and investment
community as a very important product.  The CLASS data was widely
circulated and reviewed.  One such review appeared in the prestigious
Journal of the American Medical Association (JAMA), on September 13,
2000. Based on a review of the data supplied by Pharmacia, the authors
of the JAMA article also reported that patients who took Celebrex had
fewer symptomatic ulcers than those who took diclofenac or ibuprofen,
two traditional NSAIDs.

However, on August 22, 2001, The Wall Street Journal reported that
Celebrex caused higher incidence of cardiovascular problems. The
Journal reported that noted cardiologists Eric J. Topol and Steven E.
Nissen, chairman and vice chairman, respectively, of cardiovascular
medicine at the Cleveland Clinic, issued a study on Celebrex which
concluded that "'current data would suggest that use of these so-called
"COX-02 inhibitors" might lead to increased cardiovascular events.'"  
Further, the Cleveland Clinic doctors concluded that Celebrex was
associated with a relatively high rate of heart attacks.  This report
was also published in the less widely circulated Journal of American
Medicine at or about the same time.  On this news, Pharmacia's stock
declined to below $40 by August 30, 2001, from the 45 range the stock
traded at in mid-August.

For more details, contact David R. Scott or Neil Rothstein by Mail: 108
Norwich Avenue, Colchester, Connecticut 06415 by Phone: 800/404-7770 by
Fax: 860/537-4432 by E-mail: drscott@scott-scott.com or
nrothstein@aol.com


PHARMACIA CORPORATION: Cauley Geller Lodges Securities Fraud Suit in NJ
-----------------------------------------------------------------------
Cauley Geller Bowman Coates & Rudman, LLP initiated a securities class
action in the United States District Court for the District of New
Jersey on behalf of purchasers of Pharmacia Corporation (NYSE: PHA)
publicly traded securities during the period between April 17, 2000 and
August 22, 2001, inclusive.

The complaint charges Pharmacia Corporation and certain of its officers
and directors with violations of the Securities and Exchange Act of
1934.  Specifically, the complaint alleges that Pharmacia marketed
Celebrex as a new type of drug that, unlike aspirin or ibuprofen,
retarded pain and inflammation without the adverse side effects of
ulcers or gastrointestinal bleeding.

During the class period, Pharmacia and its partner Pfizer, who funded
the study, trumpeted the results of the "Celecoxib Long-term Arthritis
Safety Study" (the "CLASS" study) -- a clinical study to compare the
gastrointestinal problems of patients who used Celebrex to those of
patients who used other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) -
- which found that Celebrex caused fewer gastrointestinal problems than
traditional drugs, such as ibuprofen.

Given all the hype surrounding the CLASS study, the Journal of the
American Medical Association (JAMA) published a study by the Company
that showed that Celebrex caused fewer gastrointestinal problems than
traditional drugs.  Unbeknownst, however, to JAMA, the study was flawed
because the Company manipulated the results in such a way to show that
Celebrex was safer for the stomach and digestive tract than
conventional drugs by not including in the final analysis all of the
data collected through the entire duration of the study, which
concluded opposite to the Company's findings.

During the class period, the Company failed to make adequate
disclosures concerning this study and used this fallacious study in
their continuing efforts to have the Food and Drug Administration
remove the warning label from Celebrex.  During the class period, the
Company continued to misrepresent that Celebrex was just as likely to
cause ulcers like older, cheaper medicines until an August 22, 2001
report in The Wall Street Journal shed light on the Company's
fallacious misrepresentations.

On August 22, 2001, The Wall Street Journal reported that reviews,
conducted by researchers from the Cleveland Clinic, of clinical trials
for the arthritis drug Celebrex indicated that the medication might
carry an increased risk for cardiovascular events.  They concluded that
heart- attack rates with Celebrex were high enough to be a concern.  
The researchers concluded: "Given the remarkable exposure and
popularity of this new class of medications, we believe that it is
mandatory to conduct a trial specifically assessing cardiovascular risk
and benefit of these agents.  Until then, we urge caution in
prescribing these agents to patients at risk for cardiovascular
morbidity."  Study author Dr. Eric Topol commented in the article that
the results are a "cautionary flag that seems to say something is going
on that needs further exploration."  On this news, Pharmacia's stock
dropped below $40 per share.

For more details, contact Samuel H. Rudman, David A. Rosenfeld, Jackie
Addison, Heather Gann or Sue Null by Mail: P.O. Box 25438, Little Rock,
AR 72221-5438 by Phone: 1-888-551-9944 by Fax: 1-501-312-8505 by E-
mail: info@cauleygeller.com


PHARMACIA CORPORATION: Schiffrin & Barroway Files Securities Suit in NJ
-----------------------------------------------------------------------
Schiffrin & Barroway, LLP initiated a securities class action filed in
the United States District Court for the District of New Jersey on
behalf of all purchasers of the common stock of Pharmacia Corporation
(NYSE:PHA) from April 17, 2000 through August 22, 2001, inclusive.

The complaint charges the Company and certain of its officers and
directors with violations of the Securities and Exchange Act of 1934.  
Specifically, the complaint alleges that Pharmacia marketed Celebrex as
a new type of drug that, unlike aspirin or ibuprofen, retarded pain and
inflammation without the adverse side effects of ulcers or
gastrointestinal bleeding.

During the class period, Pharmacia and its partner Pfizer, who funded
the study, trumpeted the results of the "Celecoxib Long-term Arthritis
Safety Study" (the "CLASS" study) -- a clinical study to compare the
gastrointestinal problems of patients who used Celebrex to those of
patients who used other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) -
- which found that Celebrex caused fewer gastrointestinal problems than
traditional drugs, such as ibuprofen.

Given all the hype surrounding the CLASS study, the Journal of the
American Medical Association (JAMA) published a study by the Company
that showed that Celebrex caused fewer gastrointestinal problems than
traditional drugs.  Unbeknownst, however, to JAMA, the study was flawed
because the Company manipulated the results in such a way to show that
Celebrex was safer for the stomach and digestive tract than
conventional drugs by not including in the final analysis all of the
data collected through the entire duration of the study, which
concluded opposite to the Company's findings.

During the class period, the Company failed to make adequate
disclosures concerning this study and used this fallacious study in
their continuing efforts to have the Food and Drug Administration
remove the warning label from Celebrex.  During the class period, the
Company continued to misrepresent that Celebrex was just as likely to
cause ulcers like older, cheaper medicines until an August 22, 2001
report in The Wall Street Journal shed light on the Company's
fallacious misrepresentations.

On August 22, 2001, The Wall Street Journal reported that reviews,
conducted by researchers from the Cleveland Clinic, of clinical trials
for the arthritis drug Celebrex indicated that the medication might
carry an increased risk for cardiovascular events.  They concluded that
heart-attack rates with Celebrex were high enough to be a concern.  The
researchers concluded: "Given the remarkable exposure and popularity of
this new class of medications, we believe that it is mandatory to
conduct a trial specifically assessing cardiovascular risk and benefit
of these agents.  Until then, we urge caution in prescribing these
agents to patients at risk for cardiovascular morbidity."  Study author
Dr. Eric Topol commented in the article that the results are a
"cautionary flag that seems to say something is going on that needs
further exploration." On this news, Pharmacia's stock dropped below $40
per share.

For more details, contact Marc A. Topaz or Stuart L. Berman by Phone:
(888) 299-7706 (toll free) or (610) 667-7706 by e-mail:
info@sbclasslaw.com


PHARMACIA CORPORATION: Alfred Yates Lodges Securities Fraud Suit in NJ
----------------------------------------------------------------------
The Law Office of Alfred G. Yates, Jr. initiated a securities class
action in the United States District Court for the District of New
Jersey on behalf of purchasers of Pharmacia Corporation (NYSE:PHA)
publicly traded securities during the period between April 17, 2000 and
August 21, 2001.

The complaint charges Pharmacia and certain of its officers and
directors with violations of the Securities Exchange Act of 1934. The
complaint alleges that according to Pharmacia, the unique feature of
Celebrex was that, unlike aspirin or ibuprofen, it allowed Celebrex to
retard pain and inflammation without the adverse side effects of
stomach malaise or gastrointestinal bleeding.  As defendants
consistently stated, this critical feature of Celebrex, provided a
tremendous market advantage because the use of traditional Nonsteroidal
Anti-inflammatory Drug (NSAIDs) resulted in as many as 100,000
hospitalizations each year and more than 15,000 deaths, related to
gastrointestinal problems such as ulcers and bleeding.

Because of its purportedly unique safety profile and its ready use by
patients, Celebrex was perceived both by the medical and investment
community as a very important product.  The CLASS data was widely
circulated and reviewed.  One such review appeared in the prestigious
Journal of the American Medical Association (JAMA), on September 13,
2000.  Based on a review of the data supplied by Pharmacia, the authors
of the JAMA article also reported that patients who took Celebrex had
fewer symptomatic ulcers than those who took diclofenac or ibuprofen,
two traditional NSAIDs.

However, on August 22, 2001, The Wall Street Journal reported that
Celebrex caused higher incidence of cardiovascular problems.  On this
news, Pharmacia's stock declined to below $40 by August 30, 2001, from
the $44-$45 range the stock traded at in mid-August.

For more details, contact the firm by Phone: 1-800-391-5164 or
412-391-5164 or by E-mail: yateslaw@aol.com.


SUPERGEN INC.: Charles Piven Lodges Securities Fraud Lawsuit in N.D. CA
-----------------------------------------------------------------------
The Law Offices Of Charles J. Piven, P.A. initiated a securities class
action on behalf of shareholders who purchased, converted, exchanged or
otherwise acquired the common stock of SuperGen, Inc. (NASDAQ: SUPG)
between April 18, 2000 and March 13, 2003, inclusive.  The case is
pending in the United States District Court for the Northern District
of California against the Company and its Chairman, President and Chief
Executive Officer.

The action charges that defendants violated federal securities laws by
issuing a series of materially false and misleading statements to the
market throughout the class period which statements had the effect of
artificially inflating the market price of the Company's securities.

For more details, contact Charles J. Piven by Mail: The World Trade
Center-Baltimore, 401 East Pratt Street, Suite 2525, Baltimore,
Maryland 21202 by Phone: 410-986-0036 or by E-mail:
hoffman@pivenlaw.com


SYMBOL TECHNOLOGIES: Marc Henzel Commences Securities Suit in E.D. NY
---------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the Eastern District of New
York on behalf of all persons and entities that acquired securities of
Symbol Technologies, Inc. (NYSE: SBL) in exchange for securities of
Telxon Corporation on or about November 30, 2000 pursuant to the merger
of Telxon and Symbol. Excluded from the Class are the Individual
Defendants (defined below) and their affiliates.  The Defendants named
in the Complaint are the Company and nine of Symbol's current and
former directors and officers:

     (1) Tomo Razmilovic,

     (2) Kenneth V. Jaeggi,

     (3) Robert W. Korkuc,

     (4) Jerome Swartz,

     (5) Harvey P. Mallement,

     (6) George Bugliarello,

     (7) Leo A. Guthart,

     (8) Charles B. Wang, and

     (9) James H. Simons

The complaint asserts that Defendants violated Sections 11, 12(a)(2)
and 15 of the Securities Act.  Plaintiff alleges in essence that the
financial statements of Symbol as of September 30, 2000, that were
contained in the Registration Statement and Joint Proxy/Prospectus for
the merger of Telxon and Symbol, were materially false and misleading
and not in conformity with Generally Accepted Accounting Principles
(GAAP).

On April 18, 2002, Symbol disclosed that the Securities and Exchange
Commission was conducting a formal inquiry into Symbol's fiscal year
2000 and 2001 financial statements.  On August 13, 2002, Symbol
announced that it might be required to restate its financial results
for all of 2000 and 2001.  Subsequently, on February 13, 2003, Symbol
announced that the scope of its accounting problems was far greater
than previously disclosed going back to 1999.

In a press release, Symbol stated "that it may have to restate its
revenue and income" for the years 1999 through 2002.  In particular,
Symbol indicated, among other things, that there would be a net
reduction in revenue and income for fiscal years 1999 and 2000.  It was
reported on March 13, 2002 that Symbol would have to restate revenue
and income for 1999 and 2000 by as much as $140 million a year.

Plaintiff alleges that Symbol's undisclosed violations of GAAP that
occurred prior to and at the time of the merger, as well as the false
and misleading financial statements and other representations included
in the Registration Statement, damaged Telxon securities holders who
received Symbol securities in the merger.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


TRANSKARYOTIC THERAPIES: Marc Henzel Commences Securities Suit in MA
---------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the District of Massachusetts
in Boston, Massachusetts on behalf of persons who purchased stock, or
who sold put options of Transkaryotic Therapies, Inc. (Nasdaq: TKTX) on
the open market from January 4, 2001 through January 14, 2003.

The complaint alleges that during the class period, defendants made
misrepresentations and nondisclosures of material fact to the investing
public concerning TKT's prospects for FDA approval of TKT's Replagal
enzyme therapy for the treatment of Fabry disease.  In fact, as the
Complaint alleges, defendants knew by virtue of their ongoing
communications with the FDA of adverse facts concerning the FDA's
consideration of TKT's application that were inconsistent with TKT's
positive representations.

More specifically, according to testimony at the January 14, 2003 FDA
Advisory Committee hearing, in a letter dated December 22, 2000, the
FDA had advised TKT that "the clinical study data (from the Phase II
studies) had not provided substantial evidence of efficiency and fully
detailed the facts leading to that conclusion.  (The FDA's Center for
Biologics Evaluation and Research) recommended that additional clinical
studies be conducted."

The true facts were all finally revealed after the January 14, 2003 FDA
Advisory Committee meeting.  On January 15, 2003, TKT closed at $6.49,
more than 85% below its class period high.  Defendants were motivated
to make the materially false and misleading statements during the class
period, among other things, so that TKT could sell $267 million in
common stock in secondary public offerings and defendant Richard F.
Selden, TKT's President and CEO, could sell 90,000 shares of his
personal holdings of TKT common stock during the class period for total
consideration of $2,800,000.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


ULTIMATE ELECTRONICS: Marc Henzel Commences Securities Fraud Suit in CO
-----------------------------------------------------------------------
The Law Offices of Marc S. Henzel initiated a securities class action
in the United States District Court for the District of Colorado, on
behalf of purchasers of Ultimate Electronics, Inc. (Nasdaq: ULTE)
publicly traded securities during the period between March 13, 2002 and
August 8, 2002, inclusive.

The complaint charges that during the class period, the defendants
issued and/or failed to correct false and misleading financial
statements and press releases concerning the Company's publicly
reported revenues and earnings directed to the investing public.

Throughout the class period, the Company maintained that it could
offset any reduction in margins incurred as a result of this transition
through continued sales of high margin items, including direct
broadcast satellite (DBS) service and systems and audio equipment.

Yet, in part to enjoy a large economic windfall as a result of its
class period offering of Ultimate stock, the Company failed to disclose
that high margin sales were decreasing rapidly and with it, a critical
stabilizer to the Company's bottom line.  On August 8, 2002 the Company
finally disclosed that because of the reduction in high margin sales,
the Company would miss its second quarter earnings EPS outlook by
almost 50%.

For more details, contact Marc S. Henzel by Mail: 273 Montgomery Ave.,
Suite 202, Bala Cynwyd, PA 19004 by Phone: 610-660-8000 or 888-643-6735
by Fax: 610-660-8080 by E-Mail: mhenzel182@aol.com or visit the firm's
Website: http://members.aol.com/mhenzel182


                              *********


S U B S C R I P T I O N   I N F O R M A T I O N

Class Action Reporter is a daily newsletter, co-published by
Bankruptcy Creditors' Service, Inc., Trenton, New Jersey, and
Beard Group, Inc., Washington, D.C.  Enid Sterling, Aurora Fatima
Antonio and Lyndsey Resnick, Editors.

Copyright 2002.  All rights reserved.  ISSN 1525-2272.

This material is copyrighted and any commercial use, resale or
publication in any form (including e-mail forwarding, electronic re-
mailing and photocopying) is strictly prohibited without prior written
permission of the publishers.

Information contained herein is obtained from sources believed to be
reliable, but is not guaranteed.

The CAR subscription rate is $575 for six months delivered via e-mail.  
Additional e-mail subscriptions for members of the same firm for the
term of the initial subscription or balance thereof are $25 each.  For
subscription information, contact Christopher Beard at 240/629-3300.

                  * * *  End of Transmission  * * *